Trial Profile
A Randomized, Controlled, Double Blind, Multicenter Study of Nimotuzumab Plus S1 Versus Placebo Plus S1 as Maintenance Treatment in Patients With Advanced or Metastatic Pancreatic Cancer After First-line Treatment
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 20 Jan 2020
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Nimotuzumab (Primary)
- Indications Liver metastases; Pancreatic cancer
- Focus Therapeutic Use
- 03 Nov 2016 New trial record